Order-made Medical Research
Order-made Medical Research Inc. (OMR) is a biotech company dedicated to revolutionizing therapeutic antibodies through innovative antibody engineering technologies. They focus on generating prominent antibodies against difficult-to-target molecules, including multi-transmembrane proteins, intracellular molecules, and disease-specific immunogenicity changes. Their mission is to create and develop therapeutic antibodies for unmet medical needs and to out-license these to pharmaceutical and biotech companies worldwide, aiming to cause a paradigm shift in future medical care.
Industries
Nr. of Employees
small (1-50)
Order-made Medical Research
5-5-4, Tokodai, Tsukuba-shi, Ibaraki 300-2635 Japan
Patents
Products
Monoclonal antibody library for SARS-CoV-2 nucleocapsid protein
Panel of approximately 20 mouse monoclonal antibodies recognizing multiple nucleocapsid epitopes, covering various IgG subclasses and reactive to multiple viral variants; intended as reagent set for antigen test kit development (distributed under NDA/MTA).
Research-use SARS-CoV-2 rapid antibody/antigen test kits (development and supply)
Rapid antibody and antigen lateral-flow style test kits developed in collaboration with partners for detecting SARS-CoV-2 antibodies or antigen; some formats released as research-use products and used in joint services by partners.
Monoclonal antibody library for SARS-CoV-2 nucleocapsid protein
Panel of approximately 20 mouse monoclonal antibodies recognizing multiple nucleocapsid epitopes, covering various IgG subclasses and reactive to multiple viral variants; intended as reagent set for antigen test kit development (distributed under NDA/MTA).
Research-use SARS-CoV-2 rapid antibody/antigen test kits (development and supply)
Rapid antibody and antigen lateral-flow style test kits developed in collaboration with partners for detecting SARS-CoV-2 antibodies or antigen; some formats released as research-use products and used in joint services by partners.
Services
Laboratory-based antigen ELISA service that reports SARS-CoV-2 antibody levels using internally developed standard antibodies and company-specific units; service offered within Japan for evaluating antibody titers pre- and post-vaccination.
Early-stage discovery and generation of therapeutic antibody leads and partnered R&D, with the intent to out-license leads to biotech and pharmaceutical companies for further development.
Laboratory-based antigen ELISA service that reports SARS-CoV-2 antibody levels using internally developed standard antibodies and company-specific units; service offered within Japan for evaluating antibody titers pre- and post-vaccination.
Early-stage discovery and generation of therapeutic antibody leads and partnered R&D, with the intent to out-license leads to biotech and pharmaceutical companies for further development.
Expertise Areas
- Therapeutic antibody discovery and engineering
- Membrane protein (multi-pass) targeting
- Internalization and payload-delivery antibodies
- Immuno-genomics and bioinformatics-driven target discovery
Key Technologies
- Cell-based immunization for membrane protein antigens
- Epitope prediction using sequence and 3D structure
- Immuno-genomics and next-generation sequencing (NGS)
- Monoclonal antibody library construction
News & Updates
The company's head office was relocated to Tsukuba-shi, Ibaraki on May 1, 2023.
The company began selling antibodies for SARS-CoV-2 antigen test kits on September 6, 2022.
The company announced the sale of their SARS-CoV-2 antibody test kit on Amazon on January 18, 2022.
The company released a SARS-CoV-2 antibody test kit for sale on December 3, 2021.
The Tsukuba Research Laboratory was established in Tsukuba-shi, Ibaraki on November 8, 2021.
The company announced the development of 'murak' antibodies for COVID-19 as pharmaceutical products on September 10, 2021.
The company's head office was relocated to Tsukuba-shi, Ibaraki on May 1, 2023.
The company began selling antibodies for SARS-CoV-2 antigen test kits on September 6, 2022.
The company announced the sale of their SARS-CoV-2 antibody test kit on Amazon on January 18, 2022.
The company released a SARS-CoV-2 antibody test kit for sale on December 3, 2021.
The Tsukuba Research Laboratory was established in Tsukuba-shi, Ibaraki on November 8, 2021.
The company announced the development of 'murak' antibodies for COVID-19 as pharmaceutical products on September 10, 2021.